Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Dequalinium is a quaternary ammonium cation antimicrobial agent used to treat common infections of the mouth and throat, as well as vaginal candidiasis. Dequalinium is an antibacterial agent with multi-targeted actions.
- Mechanism
- Curator reviewed · 13 references
Dequalinium has multiple modes of action. Dequalinium absorbs into the bacterial cell surface and diffuses through the cell wall, disrupting bacterial cell permeability. It is taken up by the bacteria rapidly. Once in the bacteria, dequalinium denatures proteins involved in the respiratory chain and glycolysis of bacteria, interfering with bacterial cell metabolism and ribosomal protein synthesis. By inhibiting bacterial F1-ATPase, dequalinium inhibits mitochondrial ATP synthesis and blocks glucose metabolism. These molecular actions ultimately deplete bacterial energy sources. As dequalinium accumulates in the mitochondria, it is considered a mitochondrial poison.
Dequalinium can also precipitate nucleic acids, as it can intercalate one of its quinoline chromophores between DNA base pairs. Depending on the drug concentration, dequalinium can lyse the bacterial cell by promoting osmotic imbalance.
- Primary indication
- Dequalinium is used in several OTC products to treat mouth infections and inflammation, such as tonsillitis, pharyngitis, and gingivitis.Curator reviewed · 16 structured indications
- Formula / weight
- C30H40N4 · 456.6654 g/mol (avg)
- First approval
- Canada, 2021
- Code names
- LSM-5846
Resolves to
PCSWXVJAIHCTMO-UHFFFAOYSA-PSMILESCC1=CC(N)=C2C=CC=CC2=[N+]1CCCCCCCCCC[N+]1=C(C)C=C(N)C2=C1C=CC=C2What you can answer from here — as of September 23, 2026
Which drugs share a target with Dequalinium, and which of those have an active Phase 3 trial?